Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
D Planas, D Veyer, A Baidaliuk, I Staropoli… - Nature, 2021 - nature.com
Abstract The SARS-CoV-2 B. 1.617 lineage was identified in October 2020 in India,,,–. Since
then, it has become dominant in some regions of India and in the UK, and has spread to …
then, it has become dominant in some regions of India and in the UK, and has spread to …
Reduced sensitivity of infectious SARS-CoV-2 variant B. 1.617. 2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
D Planas, D Veyer, A Baidaliuk, I Staropoli… - Biorxiv, 2021 - biorxiv.org
Abstract The SARS-CoV-2 B. 1.617 lineage emerged in October 2020 in India–. It has since
then become dominant in some indian regions and further spread to many countries. The …
then become dominant in some indian regions and further spread to many countries. The …
Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …
variants were first identified in the United Kingdom and South Africa, respectively, and have …
Delta variant (B. 1.617. 2) sublineages do not show increased neutralization resistance
P Arora, A Kempf, I Nehlmeier, L Graichen… - Cellular & molecular …, 2021 - nature.com
The emergence of SARS-CoV-2 variants threatens efforts to control the COVID-19
pandemic. At present, the global spread of the Delta (B. 1.617. 2) variant is responsible for a …
pandemic. At present, the global spread of the Delta (B. 1.617. 2) variant is responsible for a …
BNT162b2-elicited neutralization of B. 1.617 and other SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve
around the world, generating new variants that are of concern on the basis of their potential …
around the world, generating new variants that are of concern on the basis of their potential …
SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion
Abstract The B. 1.617. 2 (Delta) variant of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread …
(SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread …
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
southern Africa, but its subsequent spread has been extensive, both regionally and globally …
[HTML][HTML] Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7
The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …
Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …
[HTML][HTML] Increased resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 to antibody neutralization
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …
continues to rage. Prospects of ending this pandemic rest on the development of effective …
相关搜索
- sars cov 2 variants
- sars cov antibody neutralization
- sars cov reduced sensitivity
- sars cov monoclonal antibodies
- sars cov immune evasion
- sars cov antibody evasion
- sars cov antibody resistance
- sars cov receptor affinity
- sars cov omicron variant
- sars cov increased resistance
- sars cov molecular basis
- neutralization resistance delta variant
- reduced sensitivity antibody neutralization
- reduced sensitivity monoclonal antibodies
- increased resistance antibody neutralization
- immune evasion molecular basis